Progress has been made in a deeper understanding of the molecular mechanisms of cancer and in the development of innovative therapeutic agents. However, the attrition rates between target discovery and drug approval remain very high. Therefore, robust translational assays and models to predict therapeutic efficiencies have become a key parameter for oncology drug discovery programs.
Experienced, multidisciplinary teams and strategic partnerships can support drug discovery projects from hit finding to Investigational New Drug (IND).
In this webinar, the featured speakers will discuss how conventional and innovative integrated technological skills should be incorporated into the oncology drug discovery process. This effort should help the selection of drug candidates faster to the clinic. The webinar will use examples of anticancer drugs aimed at overcoming breast cancer resistance by following a multiple-step program which includes:
- Target expression/validation to identify the most effective therapeutic strategies
- In vitro screening and phenotypic assays, to select active compounds, confirm activity and better understand the mechanism of action
- Early absorption, distribution, metabolism and excretion (ADME), to establish developability potential of entities
- In vivo validation to evaluate the dose effect and therapeutic index of the compounds
- In vivo clinical drug positioning
Olivier Duchamp, Head of In Vivo sciences, Oncodesign Service Business Unit at Oncodesign
Olivier Duchamp is the head of the In Vivo Sciences Department at Oncodesign BU Service. He was at the founding of the company and for the last 26 years, contributed largely to its development and innovation in preclinical models and pharmaco-imaging. He holds a bachelor’s degree from the University of Lyon (France) and a master’s degree in pharmacology and analytical methods from the University of Paris IV (France).
Olivier is also the coordinator of IMODI, (Innovative MODels Initiative), a French consortium dedicated to the development, the characterization and the commercialization of new preclinical models in oncology, including PDX models and humanized mouse models. He is the co-author of several publications about PDX models.Message Presenter
Jean-François Mirjolet, Head of In Vitro sciences, Oncodesign Service Business Unit at Oncodesign
Jean-François Mirjolet is the head of the In Vitro Sciences Department at Oncodesign BU Service. He has been working for Oncodesign for 17 years, going through various positions from study director, technology director to his current role, managing both services and R&D related in vitro activities.
He obtained his PhD from the University of Nancy (France) in cellular pharmacology of anticancer drugs, followed by post-doctoral position at the IRIBHM, Brussels (Belgium) in chemokines and chemokine receptors implication in cancer cell migration.Message Presenter
Who Should Attend?
This webinar will be of interest to scientists from pharma companies, biotech companies and academia, working in the areas of oncology and immuno-oncology. Relevant job titles include, but are not limited to:
- Project Managers
- Study Directors
- Chief Scientific Officers
What You Will Learn
- A continuum of expertise in preclinical anticancer pharmacology and immuno-oncology by INPACT – Oncology
- Translational models and services suitable for evaluating oncology therapeutics
- Case studies focused on the drug discovery process related to breast cancer resistance
Oncodesign is a biopharmaceutical company dedicated to precision medicine, founded in 1995 by its current CEO and majority shareholder, and has been listed on Euronext Growth Market since April 2014. Its mission is the discovery of effective therapies to fight cancer and other diseases without therapeutic solutions. With its unique experience acquired by working with more than 1000 clients, including the world’s largest pharmaceutical companies, along with its unique technological platform combining artificial intelligence, state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis and medical imaging, Oncodesign is able to select new therapeutic targets, as well as design and develop potential preclinical candidates through to clinical phases.
Oncodesign has configured its organization to offer innovative services to its customers and to license its proprietary molecules. Applied to kinase inhibitors, which represent a market estimated at over $65 billion by 2027 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with global pharmaceutical groups. Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 230 employees within 3 Business Units (BU): Service, Biotech, Artificial Intelligence and subsidiaries in Canada and the USA.